Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report)'s stock price was up 4.3% on Wednesday . The stock traded as high as $14.09 and last traded at $14.10. Approximately 1,233,306 shares changed hands during trading, a decline of 76% from the average daily volume of 5,224,116 shares. The stock had previously closed at $13.51.
Analyst Ratings Changes
Several research analysts recently weighed in on ELAN shares. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday. Piper Sandler dropped their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Finally, Stifel Nicolaus upped their price target on Elanco Animal Health from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, May 19th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and an average price target of $15.17.
Read Our Latest Research Report on ELAN
Elanco Animal Health Trading Up 0.1%
The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46. The company has a fifty day moving average of $12.39 and a 200-day moving average of $11.51. The firm has a market capitalization of $7.11 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.80 and a beta of 1.67.
Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period last year, the company earned $0.34 earnings per share. Elanco Animal Health's quarterly revenue was down 1.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Elanco Animal Health
Several hedge funds have recently bought and sold shares of ELAN. FMR LLC increased its position in Elanco Animal Health by 1,153.6% during the fourth quarter. FMR LLC now owns 40,232,327 shares of the company's stock worth $487,213,000 after buying an additional 37,022,891 shares during the last quarter. Nuveen LLC acquired a new position in Elanco Animal Health during the first quarter worth $115,212,000. Norges Bank acquired a new position in Elanco Animal Health during the fourth quarter worth $47,424,000. Dimensional Fund Advisors LP increased its position in Elanco Animal Health by 14.3% during the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after buying an additional 2,563,740 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.
Elanco Animal Health Company Profile
(
Get Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Further Reading
Before you consider Elanco Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elanco Animal Health wasn't on the list.
While Elanco Animal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
